Effects of the GLP-1 Receptor Agonist Dulaglutide on the Structure of the Exocrine Pancreas of Cynomolgus Monkeys.

Vahle JL, Byrd RA, Blackbourne JL, Martin JA, Sorden SD, Ryan T, Pienkowski T, Rosol TJ, Snyder PW, Klöppel G

Toxicologic pathology9 Jun 2015Cited by 5 (Europe PMC)

PMID26059826DOI10.1177/0192623315588999PepBankPUB-26059826

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study12

12 results from studies that gave the peptide. No result from this study comes from people.

01AnimalAnimal study (in vivo)Safety outcome
In monkeys, dulaglutide increased goblet cells in 4 of 19 treated animals.
In plain wordsIn monkeys, dulaglutide increased goblet cells in 4 of 19 treated animals.
Peptide
Dulaglutide (Trulicity)
Outcome
IncreaseGoblet cells
Study
cynomolgus monkeysn = 19
nondiabetic monkeys
Comparator
control
Outcome group
Adverse events · Gastrointestinal
Studied dose
8.15 mg/kg twice weekly · 12 monthsAs given in this study (cynomolgus monkeys).
Source sentences
Summary
An increase in goblet cells noted in 4 of the 19 treated monkeys was considered an effect of dulaglutide but was not associated with dilation, blockage, or accumulation of mucin in the pancreatic duct.
1 context sentence(design, population, supporting numbers)
Summary · context
Dulaglutide 8.15 mg/kg (approximately 500 times the maximum recommended human dose based on plasma exposure) was administered twice weekly for 12 months to cynomolgus monkeys.
Report a problemFND-2605982608
02AnimalAnimal study (in vivo)Safety outcome
In monkeys, dulaglutide did not alter serum amylase activity versus control.
In plain wordsIn monkeys, dulaglutide did not change serum amylase activity versus control.
Peptide
Dulaglutide (Trulicity)
Outcome
No significant changeSerum amylase
Study
cynomolgus monkeysn: not reported in source
nondiabetic monkeys
Comparator
control
Outcome group
Adverse events · Gastrointestinal
Studied dose
8.15 mg/kg twice weekly · 12 monthsAs given in this study (cynomolgus monkeys).
Source sentences
Summary
Dulaglutide administration did not alter serum amylase or lipase activities measured at the end of treatment compared to control values.
1 context sentence(design, population, supporting numbers)
Summary · context
Dulaglutide 8.15 mg/kg (approximately 500 times the maximum recommended human dose based on plasma exposure) was administered twice weekly for 12 months to cynomolgus monkeys.
Report a problemFND-2605982601
03AnimalAnimal study (in vivo)Safety outcome
In monkeys, dulaglutide did not alter serum lipase activity versus control.
In plain wordsIn monkeys, dulaglutide did not change serum lipase activity versus control.
Peptide
Dulaglutide (Trulicity)
Outcome
No significant changeSerum lipase
Study
cynomolgus monkeysn: not reported in source
nondiabetic monkeys
Comparator
control
Outcome group
Adverse events · Gastrointestinal
Studied dose
8.15 mg/kg twice weekly · 12 monthsAs given in this study (cynomolgus monkeys).
Source sentences
Summary
Dulaglutide administration did not alter serum amylase or lipase activities measured at the end of treatment compared to control values.
1 context sentence(design, population, supporting numbers)
Summary · context
Dulaglutide 8.15 mg/kg (approximately 500 times the maximum recommended human dose based on plasma exposure) was administered twice weekly for 12 months to cynomolgus monkeys.
Report a problemFND-2605982602
04AnimalAnimal study (in vivo)Safety outcome
In monkeys given dulaglutide, pancreatic acinar portions showed no histologic changes.
In plain wordsIn monkeys given dulaglutide, pancreatic acinar tissue showed no changes.
Peptide
Dulaglutide (Trulicity)
Outcome
No significant changeAcinar histology
Study
cynomolgus monkeysn: not reported in source
nondiabetic monkeys
Comparator
control
Outcome group
Adverse events · Gastrointestinal
Studied dose
8.15 mg/kg twice weekly · 12 monthsAs given in this study (cynomolgus monkeys).
Source sentences
Summary
An extensive histologic evaluation of the pancreas revealed no changes in the acinar or endocrine portions and no evidence of pancreatitis, necrosis, or pancreatic intraepithelial neoplasia.
1 context sentence(design, population, supporting numbers)
Summary · context
Dulaglutide 8.15 mg/kg (approximately 500 times the maximum recommended human dose based on plasma exposure) was administered twice weekly for 12 months to cynomolgus monkeys.
Report a problemFND-2605982603
05AnimalAnimal study (in vivo)Safety outcome
In monkeys given dulaglutide, endocrine pancreatic portions showed no histologic changes.
In plain wordsIn monkeys given dulaglutide, endocrine pancreatic tissue showed no changes.
Peptide
Dulaglutide (Trulicity)
Outcome
No significant changeEndocrine pancreatic histology
Study
cynomolgus monkeysn: not reported in source
nondiabetic monkeys
Comparator
control
Outcome group
Adverse events · Gastrointestinal
Studied dose
8.15 mg/kg twice weekly · 12 monthsAs given in this study (cynomolgus monkeys).
Source sentences
Summary
An extensive histologic evaluation of the pancreas revealed no changes in the acinar or endocrine portions and no evidence of pancreatitis, necrosis, or pancreatic intraepithelial neoplasia.
1 context sentence(design, population, supporting numbers)
Summary · context
Dulaglutide 8.15 mg/kg (approximately 500 times the maximum recommended human dose based on plasma exposure) was administered twice weekly for 12 months to cynomolgus monkeys.
Report a problemFND-2605982604
06AnimalAnimal study (in vivo)Safety outcome
In monkeys given dulaglutide, histology showed no pancreatitis.
In plain wordsIn monkeys given dulaglutide, tissue examination showed no pancreatitis.
Peptide
Dulaglutide (Trulicity)
Outcome
Not applicablePancreatitis
Study
cynomolgus monkeysn: not reported in source
nondiabetic monkeys
Comparator
control
Outcome group
Adverse events · Gastrointestinal
Studied dose
8.15 mg/kg twice weekly · 12 monthsAs given in this study (cynomolgus monkeys).
Source sentences
Summary
An extensive histologic evaluation of the pancreas revealed no changes in the acinar or endocrine portions and no evidence of pancreatitis, necrosis, or pancreatic intraepithelial neoplasia.
1 context sentence(design, population, supporting numbers)
Summary · context
Dulaglutide 8.15 mg/kg (approximately 500 times the maximum recommended human dose based on plasma exposure) was administered twice weekly for 12 months to cynomolgus monkeys.
Report a problemFND-2605982605
07AnimalAnimal study (in vivo)Safety outcome
In monkeys given dulaglutide, histology showed no pancreatic necrosis.
In plain wordsIn monkeys given dulaglutide, tissue examination showed no pancreatic tissue death.
Peptide
Dulaglutide (Trulicity)
Outcome
Not applicablePancreatic necrosis
Study
cynomolgus monkeysn: not reported in source
nondiabetic monkeys
Comparator
control
Outcome group
Adverse events · Gastrointestinal
Studied dose
8.15 mg/kg twice weekly · 12 monthsAs given in this study (cynomolgus monkeys).
Source sentences
Summary
An extensive histologic evaluation of the pancreas revealed no changes in the acinar or endocrine portions and no evidence of pancreatitis, necrosis, or pancreatic intraepithelial neoplasia.
1 context sentence(design, population, supporting numbers)
Summary · context
Dulaglutide 8.15 mg/kg (approximately 500 times the maximum recommended human dose based on plasma exposure) was administered twice weekly for 12 months to cynomolgus monkeys.
Report a problemFND-2605982606
08AnimalAnimal study (in vivo)Safety outcome
In monkeys given dulaglutide, histology showed no pancreatic intraepithelial neoplasia.
In plain wordsIn monkeys given dulaglutide, examination showed no pancreatic intraepithelial neoplasia.
Peptide
Dulaglutide (Trulicity)
Outcome
Not applicablePancreatic intraepithelial neoplasia
Study
cynomolgus monkeysn: not reported in source
nondiabetic monkeys
Comparator
control
Outcome group
Adverse events · Gastrointestinal
Studied dose
8.15 mg/kg twice weekly · 12 monthsAs given in this study (cynomolgus monkeys).
Source sentences
Summary
An extensive histologic evaluation of the pancreas revealed no changes in the acinar or endocrine portions and no evidence of pancreatitis, necrosis, or pancreatic intraepithelial neoplasia.
1 context sentence(design, population, supporting numbers)
Summary · context
Dulaglutide 8.15 mg/kg (approximately 500 times the maximum recommended human dose based on plasma exposure) was administered twice weekly for 12 months to cynomolgus monkeys.
Report a problemFND-2605982607
09AnimalAnimal study (in vivo)Safety outcome
In monkeys, the dulaglutide-associated goblet cell increase was not associated with pancreatic duct dilation.
In plain wordsIn monkeys, the goblet cell increase with dulaglutide was not associated with pancreatic duct dilation.
Peptide
Dulaglutide (Trulicity)
Outcome
Not applicablePancreatic duct dilation
Study
cynomolgus monkeysn: not reported in source
nondiabetic monkeys
Comparator
control
Outcome group
Adverse events · Gastrointestinal
Studied dose
8.15 mg/kg twice weekly · 12 monthsAs given in this study (cynomolgus monkeys).
Source sentences
Summary
An increase in goblet cells noted in 4 of the 19 treated monkeys was considered an effect of dulaglutide but was not associated with dilation, blockage, or accumulation of mucin in the pancreatic duct.
1 context sentence(design, population, supporting numbers)
Summary · context
Dulaglutide 8.15 mg/kg (approximately 500 times the maximum recommended human dose based on plasma exposure) was administered twice weekly for 12 months to cynomolgus monkeys.
Report a problemFND-2605982609
10AnimalAnimal study (in vivo)Safety outcome
In monkeys, the dulaglutide-associated goblet cell increase was not associated with pancreatic duct blockage.
In plain wordsIn monkeys, the goblet cell increase with dulaglutide was not associated with pancreatic duct blockage.
Peptide
Dulaglutide (Trulicity)
Outcome
Not applicablePancreatic duct blockage
Study
cynomolgus monkeysn: not reported in source
nondiabetic monkeys
Comparator
control
Outcome group
Adverse events · Gastrointestinal
Studied dose
8.15 mg/kg twice weekly · 12 monthsAs given in this study (cynomolgus monkeys).
Source sentences
Summary
An increase in goblet cells noted in 4 of the 19 treated monkeys was considered an effect of dulaglutide but was not associated with dilation, blockage, or accumulation of mucin in the pancreatic duct.
1 context sentence(design, population, supporting numbers)
Summary · context
Dulaglutide 8.15 mg/kg (approximately 500 times the maximum recommended human dose based on plasma exposure) was administered twice weekly for 12 months to cynomolgus monkeys.
Report a problemFND-2605982610
11AnimalAnimal study (in vivo)Safety outcome
In monkeys, the dulaglutide-associated goblet cell increase was not associated with pancreatic duct mucin accumulation.
In plain wordsIn monkeys, the goblet cell increase with dulaglutide was not associated with mucin accumulation in pancreatic ducts.
Peptide
Dulaglutide (Trulicity)
Outcome
Not applicablePancreatic duct mucin accumulation
Study
cynomolgus monkeysn: not reported in source
nondiabetic monkeys
Comparator
control
Outcome group
Adverse events · Gastrointestinal
Studied dose
8.15 mg/kg twice weekly · 12 monthsAs given in this study (cynomolgus monkeys).
Source sentences
Summary
An increase in goblet cells noted in 4 of the 19 treated monkeys was considered an effect of dulaglutide but was not associated with dilation, blockage, or accumulation of mucin in the pancreatic duct.
1 context sentence(design, population, supporting numbers)
Summary · context
Dulaglutide 8.15 mg/kg (approximately 500 times the maximum recommended human dose based on plasma exposure) was administered twice weekly for 12 months to cynomolgus monkeys.
Report a problemFND-2605982611
12AnimalAnimal study (in vivo)Safety outcome
In monkeys, ductal epithelial proliferation did not differ between dulaglutide and control.
In plain wordsIn monkeys, ductal cell growth did not differ between dulaglutide and control.
Peptide
Dulaglutide (Trulicity)
Outcome
No significant changeDuctal epithelial proliferation
Study
cynomolgus monkeysn: not reported in source
nondiabetic monkeys
Comparator
control
Outcome group
Adverse events · Gastrointestinal
Studied dose
8.15 mg/kg twice weekly · 12 monthsAs given in this study (cynomolgus monkeys).
Source sentences
Summary
There was no difference in cell proliferation in ductal epithelium between control and dulaglutide-treated monkeys.
1 context sentence(design, population, supporting numbers)
Summary · context
Dulaglutide 8.15 mg/kg (approximately 500 times the maximum recommended human dose based on plasma exposure) was administered twice weekly for 12 months to cynomolgus monkeys.
Report a problemFND-2605982612

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.